Latest News
A combination of two immunotherapy drugs benefits people with kidney cancer
Results from the RAMPART trial show that giving durvalumab and tremelimumab after surgery helps prevent kidney cancer coming back.
Weekly chemotherapy with bevacizumab improves ovarian cancer survival compared to having it once every three weeks
New results from the ICON8B trial were presented at the ESMO 2025 Conference.
Largest-ever Parkinson’s disease trial opens across UK
Using our multi-arm, multi-stage design, the EJS ACT-PD clinical trial aims to slow or stop the progression of Parkinsons’ disease.
Spotlight on our research at ESMO Congress 2025
We will present our latest cancer research from the RAMPART, ICON8B and STAMPEDE trials and STOPCAP meta-analysis at the 2025 ESMO Congress.